Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season.

IF 7.8 2区 医学 Q1 INFECTIOUS DISEASES Eurosurveillance Pub Date : 2025-02-01 DOI:10.2807/1560-7917.ES.2025.30.6.2500040
Roberto Pastor-Barriuso, Olivier Núñez, Susana Monge
{"title":"Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season.","authors":"Roberto Pastor-Barriuso, Olivier Núñez, Susana Monge","doi":"10.2807/1560-7917.ES.2025.30.6.2500040","DOIUrl":null,"url":null,"abstract":"<p><p>Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 6","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914966/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.6.2500040","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
西班牙,2023/24季节,婴儿需要接种nirseimab以预防一例呼吸道合胞病毒住院。
使用2023年10月至2024年3月期间西班牙的真实数据,估计使用nirsevimab进行免疫(NNI)所需的数量和预防一次RSV住院的费用为90名婴儿(95% CI: 77-108)和19,700欧元的补种免疫接种,41名婴儿(95% CI: 35-50)和9,000欧元的出生免疫接种。按出生月份计算,在RSV流行高峰前不久出生的婴儿NNI和费用最低,越早或越晚出生的影响逐渐降低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Eurosurveillance
Eurosurveillance INFECTIOUS DISEASES-
CiteScore
32.70
自引率
2.10%
发文量
430
审稿时长
3-8 weeks
期刊介绍: Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
期刊最新文献
Design and implementation of an evaluation framework for the Epidemic Intelligence from Open Sources (EIOS) system for international public health intelligence at the Robert Koch Institute, Germany, 2023. Detection of Aeromonas, Campylobacter and Salmonella using concurrent bacterial culture and commercial multiplex PCR, Sydney, Australia, 2023. Interim 2025/26 influenza vaccine effectiveness estimates with immuno-epidemiological considerations for A(H3N2) subclade K protection, Canada, January 2026. Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. Cross-sectional study on protective antibodies against influenza A virus subtypes and cross-protection against influenza A(H3N2) subclade K, Portugal, August 2025.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1